Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity 44(5), 1069–1078 (2016).
  Medline CASGoogle Scholar
• 2. Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat. Med. 25(3), 389–402 (2019).
  Medline CASGoogle Scholar
• 3. Ren D, Hua Y, Yu B et al. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol. Cancer 19(1), 19 (2020).
  MedlineGoogle Scholar
• 4. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17(12), e542–e551 (2016).
  Medline CASGoogle Scholar
• 5. Aguiar PN Jr, Santoro IL, Tadokoro H et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8(4), 479–488 (2016).
  CASGoogle Scholar
• 6. Signorelli D, Giannatempo P, Grazia G et al. Patients selection for immunotherapy in solid tumors: overcome the naive vision of a single biomarker. Biomed. Res. Int. 2019, 9056417 (2019).
  MedlineGoogle Scholar
• 7. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1–10 (2013).
  MedlineGoogle Scholar
• 8. Colli LM, Machiela MJ, Zhang H et al. Landscape of combination immunotherapy and targeted therapy to improve cancer management. Cancer Res. 77(13), 3666–3671 (2017). • Reviews the current predictive factors for treatment of immune checkpoint inhibitors treatment.
  Medline CASGoogle Scholar
• 9. Tu MM, Lee FYF, Jones RT et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci. Adv. 5(2), eaav2437 (2019).
  Medline CASGoogle Scholar
• 10. Toumpeki C, Liberis A, Tsirkas I et al. The role of ARID1A in endometrial cancer and the molecular pathways associated with pathogenesis and cancer progression. In Vivo 33(3), 659–667 (2019).
  Medline CASGoogle Scholar
• 11. Fukumoto T, Magno E, Zhang R. SWI/SFN complexes in ovarian cancer: mechanistic insights and therapeutic implications. Mol. Cancer Res. 16(12), 1819–1825 (2018).
  Medline CASGoogle Scholar
• 12. Mathur R. ARID1A loss in cancer: towards a mechanistic understanding. Pharmacol. Ther. 190, 15–23 (2018).
  Medline CASGoogle Scholar
• 13. Shen J, Ju Z, Zhao W et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat. Med. 24(5), 556–562 (2018).
  Medline CASGoogle Scholar
• 14. Li L, Li M, Jiang Z, Wang X. ARID1A mutations are associated with increased immune activity in gastrointestinal Cancer. Cells 8(7), pii: E678 (2019).
  Google Scholar
• 15. Li J, Wang W, Zhang Y et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J. Clin. Invest. pii: 134402 (2020). • Summarizes about ARID1A alteration and function in cancer development and tumor immunity.
  Google Scholar
• 16. Li T, Fan J, Wang B et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77(21), e108–e110 (2017).
  Medline CASGoogle Scholar
• 17. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401–404 (2012).
  MedlineGoogle Scholar
• 18. Zehir A, Benayed R, Shah RHet al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10000 patients. Nat Med. 23(6), 703–713(2017).
  Medline CASGoogle Scholar
• 19. Cheng DT, Mitchell TN, Zehir A et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17(3), 251–264 (2015).
  Medline CASGoogle Scholar
• 20. Samstein RM, Lee CH, Shoushtari AN et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202–206 (2019).
  Medline CASGoogle Scholar
• 21. Thorsson V, Gibbs DL, Brown SD et al. The immune landscape of cancer. Immunity 48(4), 812–830 (2018).
  Medline CASGoogle Scholar
• 22. Saltz J, Gupta R, Hou L et al. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep. 23(1), 181–193 (2018). • Introduces several online public database used in this study.
  Medline CASGoogle Scholar
• 23. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348(6230), 56–61 (2015).
  Medline CASGoogle Scholar
• 24. Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity 52(1), 55–81 (2020).
  Medline CASGoogle Scholar
• 25. Fridman WH Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12(4), 298–306 (2012).
  Medline CASGoogle Scholar
• 26. Horton BL, Fessenden TB, Spranger S. Tissue site and the cancer immunity cycle. Trends Cancer 5(10), 593–603 (2019).
  Medline CASGoogle Scholar
• 27. Liu C, Zheng S, Jin R et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 470, 95–105 (2020).
  Medline CASGoogle Scholar
• 28. Lhuillier C, Rudqvist NP, Elemento O, Formenti SC, Demaria S. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med. 11(1), 40 (2019).
  MedlineGoogle Scholar
• 29. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1–2), 48–61 (2015). •• The complexity and diversity of tumor immune microenvironment makes it difficult to explore powerful predictors for immunotherapy. It is urgent to find a new direction on predictor exploration for immunotherapy response.
  Medline CASGoogle Scholar
• 30. Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers 8(3), 1–12 (2016).
  Google Scholar
• 31. Murphy KA, Bhamidipati K, Rubin SJS, Kipp L, Robinson WH, Lanz TV. Immunomodulatory receptors are differentially expressed in B and T cell subsets relevant to autoimmune disease. Clin. Immunol. 209, 108276 (2019).
  Medline CASGoogle Scholar
• 32. Eivazi S, Bagheri S, Hashemzade MS et al. Development of T follicular helper cells and their role in disease and immune system. Biomed. Pharmacother. 84, 1668–1678 (2017).
  Google Scholar
• 33. Asadzadeh Z, Mohammadi H, Safarzadeh E et al. The paradox of Th17 cell functions in tumor immunity. Cell. Immunol. 322, 15–25 (2017).
  Medline CASGoogle Scholar
• 34. Stockis J, Roychoudhuri R, Halim TYF. Regulation of regulatory T cells in cancer. Immunology 157(3), 219–231 (2019).
  Medline CASGoogle Scholar
• 35. Hollern DP, Xu N, Thennavan A et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179(5), 1191–1206 (2019). • Various subtypes of T and B cells existed in tumor immune microenvironment exhbits complex and different function in cancer immunity.
  Medline CASGoogle Scholar
• 36. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200–218 (2020).
  Medline CASGoogle Scholar
• 37. Den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ. Dendritic cells: tools and targets for antitumor vaccination. Expert Rev. Vaccines 4(5), 699–710 (2005).
  MedlineGoogle Scholar
• 38. Jeong J, Suh Y, Jung K. Context drives diversification of monocytes and neutrophils in orchestrating the tumor microenvironment. Front. Immunol. 10, 1817 (2019).
  Medline CASGoogle Scholar
• 39. Tamura R, Tanaka T, Yamamoto Y, Akasaki Y, Sasaki H. Dual role of macrophage in tumor immunity. Immunotherapy 10(10), 899–909 (2018).
  CASGoogle Scholar
• 40. Varricchi G, Galdiero MR, Loffredo S et al. Are mast cells MASTers in cancer? Front. Immunol. 8, 424 (2017).
  MedlineGoogle Scholar
• 41. Wouters MCA, Nelson BHP. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24(24), 6125–6135 (2018). • Complex and diverse roles of other subtypes of immune cells including NK cells, monocytes, macrophage and plasma cells in tumor immunity.
  Medline CASGoogle Scholar
• 42. Tang H, Wang Y, Chlewicki LK et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29(3), 285–296 (2016).
  Medline CASGoogle Scholar